CRA analyzed market definition in antitrust litigation concerning a product in the non-opioid pain category. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing.
Keler Marku joins CRA's Antitrust & Competition Practice
“We are pleased to welcome Keler back to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Keler is an expert in...